Prof. Masao Omata was the Chairman of the Department of Gastroenterology at the University of Tokyo, Japan. He graduated from the Chiba University School of Medicine and continued his training at Yale University, USA and in the Liver Unit at the University of Southern California. In 1992, he became Chairman of the Second Department of Internal Medicine at the University of Tokyo, Japan and then subsequently became Chairman of the Department of Gastroenterology. Under his leadership, the Department of Gastroenterology had become one of the foremost centers in its field.
In 2009, he was promoted to become the president of two hospitals: Yamanashi Central and Kita Hospitals to upgrade the medical care system in Yamanashi Prefecture, west of Tokyo, where, although scenic place with Mt. Fuji, hepatitis virus infection is endemic. The governor of Yamanashi has asked Prof. Omata to combat with the liver diseases of his homeland under his expertise and also run the two hospitals as a president.
Prof. Omata has made numerous seminal contributions to the fields of gastroenterology, hepatology, HBV and HCV, including the first description of the association between pre-core HBV mutants and fulminant hepatitis (N Engl J Med 1991), and the extremely high eradication rate of acute HCV by interferon (Lancet 1991). In addition, his group was the first to document the presence of cccDNA of HBV in human samples as a key marker of antiviral resistance (Hepatology 1985). Other major contributions include the emphasis of a viral etiology for hepatocellular carcinoma in 1970s in the USA (Gastroenterology 1979), as well as the first description of ‘fibrolamellar carcinoma’ (Cancer 1980).
He also demonstrated that the eradication of HCC decreased the incidence to one-fifth of the untreated, and fibrosis regression rate was 0.28 Fibrosis Stages/year. He also has established the largest volume center of HCC treatment by educating more than 200 young hepatologists and gastroenterologists at the University of Tokyo.
He has published over 950 articles in peer-reviewed English journals (5 N Engl J Med, 6 Lancet, 40 Gastroenterology, 53 Hepatology) in all disciplines of gastroenterology and hepatology (total impact factors: 4145, total citations: 20375 times).
He was the Presidents of the 17th Asian Pacific Association for the Study of the Liver (APASL) in 2007 and the 50th Japanese Society of Gastroenterology meeting in 2008. Currently, he is in charge of APASL-Tokyo-Secretariat.
HBV; HCV; HCC
Prof. Shu-Kui Qin, President of Chinese Society of Clinical Oncology (CSCO) and Vice-President of Nanjing Bayi Hospital and Director of PLA Cancer Center, is a senior medical oncologist, especially focusing on the Gastro-intestinal cancer and Liver cancer.
Prof.Qin holds some important positions in a variety of international and domestic academic organizations, including Council Member of Asia Clinical Oncology Society (ACOS), Senior Council Member of Chinese Anti-Cancer Association (CACA), Vice- President of the National Committee for Cancer Palliative Therapy & Pain Control, Chair of Liver Cancer group of National Ministry of Health, etc. He acts as the Editor-in- Chief of “Journal of Chinese Clinical Oncology” and “The Oncologist (Chinese version) ” , the Associate Editor-in-Chief of “Chinese Clinical Oncology Year-Books”, “Journal of Cancer Research and Clinical” and “The Chinese-German Journal of Clinical Oncology” etc.
Up to now, Prof. Qin has published more than 400 medical papers and 45 academic works, has participated in more than 82 international multi-centers clinical trials and 51 domestic clinical trials. Prof. Qin’s outstanding contributions to both academic and research fields were highly rewarded including Special Talent Allowance of State Council and more than 16 Chinese National and Province scientific awards.
Gastro-intestinal cancer; liver cancer
Dr. Buell is the Director of the Tulane Transplant Institute and Director of Transplantation at the New Orleans Children’s Hospital, the Louisiana State University. Currently, Dr. Buell is a tenured Professor of Surgery and Pediatrics at Tulane University and the Louisiana State University. Dr. Buell has clinical interests in drug and medical device development including clinical immunology and stem cell technology. His medical interests are in health care disparity, medical economics, health policy, and systems development. Dr. Buell’s expertise is in liver and bile duct cancer, as well as solid organ and composite tissue transplantation.
Dr. Buell received his undergraduate from Fordham University in New York City and subsequently earned his medical degree from the University of Rochester, and a Mater’s of Business Administration from Tulane University. Dr. Buell completed his general surgery residency at the University of Maryland and Shock Trauma Center. Dr. Buell subsequently completed two fellowships, the first in surgical oncology at the National Cancer Center, National Institutes of Health and the second his multi-organ transplant fellowship at the University of Chicago. Dr. Buell has received numerous awards and fellowships including The Dr. Leak award from the American Cancer Society. Dr. Buell was trained as a basic scientist at the National Cancer Institute, National Institutes of Health and completed his post-doctoral research in the molecular mechanisms of DNA platination and the implications of hyperthermia and tumor necrosis factor in the modification of snip gene transcription.
Subsequently, Dr. Buell pioneered the field of laparoscopic liver surgery has become a thought leader in device development, clinical trials and translational research. Since his arrival in New Orleans he has re-organized and realigned the Tulane and Louisiana State University programs to provide comprehensive transplant and liver tumor care for adults and children in the greater Louisiana region. In this region with significant financial and racial disparity, Dr. Buell and his collaborator Dr. Friedlander have worked with the ministers of the Ninth Ward to address systemic and regional racial disparity to provide improved healthcare to the most financially disparite.
Transplantation & Hepatobiliary
4. Minimally invasive liver surgery
Guangwen Cao is the chairman of the Department of Epidemiology, Second Military Medical University (Shanghai, China). He was graduated from Second Military Medical University as PhD and MD student and received medical trainings in Baylor College of Medicine and University of Texas MD Anderson Cancer Center (Houston, USA). Prof. Cao serves as the principal scientist of the National Key Basic Research Program (973 program) in cancer research and the Distinguished Young Scholar in China. Prof. Cao has published 120 research papers in international journals.
Biomarkers and genetic disposition on carcinogenesis and metastasis of hepatocellular carcinoma; renal cell carcinoma; lung cancer; gastric cancer; colorectal carcinoma; infectious cause of hepatocellular carcinoma; interaction between hepatitis B virus and genetic predisposition on hepatocarcinogenesis; quick pathogen identification and epidemiological outbreak study of emerging infectious diseases of natural sources and manmade; disaster medicine
Prof. Farinati Fabio graduated in medicine and surgery with full marks and laude Padua University, Italy in 1978. then received his MD specialization in gastroenterology with full marks and Laude, Padua University in 1982, and PhD specialization in oncology, Padua University in 1987. Now he is the full professor of gastroenterology, department of surgical and gastroenterological sciences, Padua University. He has more than 280 publications in PubMed with an IF > 1,000 in highly ranked international scientific journals, 55 full papers in Italian journals, has written 42 book chapters.
GI cancerogenesis and clnical practice, with specific interest in gastric and liver cancer, precancerous conditions and lesions in esophagus and stomach.
•Responsible for grants by the Italian Ministry of Health and University and other private and public organization.
•Coordinator of the GENE group (Hepatocarcinoma Group North East Italy)
•Coordinator of the Section of Oncology of the Italian Society of Gastroenterology
•Vice President of the Italian Society of Gastroenterology
Mark Feitelson attended Cypress College (Cypress, CA) from 1970-72, and then received a BS degree in Biology from the University of California, Irvine in 1974. Advanced studies resulted in a PhD in Microbiology and Immunology from the UCLA School of Medicine in 1979. His thesis presented the genetic organization of the rabbit papilloma virus. He was then an American Cancer Society Postdoctoral fellow in the Department of Medicine at Stanford University from 1980-1982, where he started his work with hepatitis B virus (HBV). He was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (who won the Nobel Prize for his discovery of HBV) where he continued his work in HBV. He is presently Professor of Biology at Temple University and Associate Director of the Temple Biotechnology Center. He has been consistently funded by NIH and foundations since 1988 for basic science work on HBV and has attracted 10 contracts from industry for translational and applied work since 1997. He has over 100 publications in highly ranked international scientific journals, has written two books; delivered more than 160 oral presentations and/or posters at national and international scientific meetings, and has delivered more than 100 invited lectureships all over the world.
Molecular pathogenesis of hepatitis B and C viruses in liver cancer; hepatitis B
Liver cancer and liver transplantation; tumor infiltration; metastasis and extended resection in liver; gallbladder and pancreas; as well as promotion of surgical technology innovation by combining medical science and engineering
Go Wakabayashi, earned his degrees from Keio University School of Medicine, Tokyo Japan. He was trained at Department of Surgery at Massachusetts General Hospital and Harvard Medical School. After working as an assistant professor at Department of Surgery, Keio University School of Medicine, he was recruited as professor and chairman of Department of surgery at Iwate Medical University School of Medicine in 2005. His expertise includes Hepato-pancreatic Biliary Surgery, liver transplantation, and laparoscopic surgery. He has operated more than 150 cases of living liver transplantation and over 3000 cases of HPB surgery and laparoscopic surgery. He was awarded Gold Medal of Video Olympics at The World Congress of Endoscopic Surgery 1996. He also practices conventional HPB surgery and aggressive surgery as well. He holds numerous important positions in Japanese and international surgical societies.
Hepato-pancreatic biliary surgery; liver transplantation; laparoscopic surgery; conventional HPB surgery and aggressive surgery
Professor Jun Yu is a Professor at Department of Medicine and Therapeutics, Director of the Research Laboratory of Institute of Digestive Disease, and Associate Director of State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong (CUHK). Prof Yu did her MD and PhD at Tongji Medical University and then she embarked on gastrointestinal specialist in Beijing University in 1994-1998, followed by a postdoctoral fellowship in the Department of Gastroenterology at the University of Dresden and University of Magdeburg, Germany and CUHK, Hong Kong, respectively in 1998-2002. She worked as a Senior Research Officer at University of Sydney in 2003-2005. She has been a CUHK faculty member since 2005. Her research interests are mainly on gastrointestinal cancers in relation to the genetic and epigenetic molecular mechanisms and cancer biomarkers. Serving as a member of International Cancer Genome Consortium (ICGC), she has also been involved in research on whole genome,exome and metagenome sequencing in gastrointestinal cancers. Prof Yu has over 280 publications in international peer-reviewed journals (51 papers with impact factor > 10) including Nature biotechnology, Cancer Cell, Cell Metabolism, J Clin Oncol, J Clin Invest, Gastroenterology, Gut, Nature communication, Hepatology, Cancer Res and Oncogene and 7 book or book chapters. She has obtained or filed 15 patents for cancer biomarkers. Her contributions to the advancement of medical sciences have been recognized with 15 prestigious awards.
Murine non-alcohol steatohepatitis (NASH) in relation to the mechanisms of development of experimental steatohepatitis; and treatment response
1. Gene modulation in protect against NASH
2. Identification of the epigenetic and genetic alterations in relation to the mechanisms of pathogenesis of hepatocellular carcinoma (HCC)
3. Identification of epigenetic and genetic targets in relation to early diagnosis and prognostic prediction of gastrointestinal cancers
Tan To Cheung, MBBS, MS, FRCS(Ed), FCSHK, FHKAM, is the Chief of the Division of Hepatobiliary and Pancreatic Surgery within the Department of Surgery, Queen Mary Hospital, the University of Hong Kong, and a Council member of the Hong Kong Society of Hepatobiliary and Pancreatic Surgery. He is also Associate Professor of Surgery at the University of Hong Kong.
Dr. Cheung received his medical degree from the University of Hong Kong. After graduation, Dr. Cheung started his career as surgeon at Queen Mary Hospital. With his interest in complicated liver surgery and liver transplantation, he became a staff member of the Division of Hepatobiliary and Pancreatic Surgery in 2006.
Dr. Cheung is one of the leading experts in laparoscopic liver resection in Hong Kong. He has performed more than 300 pure laparoscopic liver hepatectomies in Hong Kong. He published the results of laparoscopic hepatectomies at Queen Mary Hospital in various journals, including Annals of Surgery and World Journal of Surgery.
He is keen on new procedure development and is an active researcher in the fields of liver transplant, complicated liver surgery, ALPPS, minimally invasive surgery for liver cancer, and the role of dual tracer PET CT in the diagnosis of HCC. Dr. Cheung has obtained his doctoral degree (Master of Surgery, HKU) with research on the treatment of HCC in liver cirrhosis. He is the world’s leading expert in the area of high intensity focused ultrasound (HIFU) therapy for HCC. He performed the first HIFU treatment as a bridging therapy for liver transplant in the world.
Dr. Cheung was a recipient of the GB Ong Travelling Fellowship Award. He has won many other awards including travelling awards, Best Oral Presentation awards, Best Video awards and Best Poster awards in various international meetings. He has authored more than 140 peer-reviewed articles and other publications, and is frequently invited to lecture internationally and to present in plenary sessions. He has mentored a large number of trainees.
liver transplant, complicated liver surgery, ALPPS, minimally invasive surgery
Dr. Hongping Xia received his M.D. degree from Wannan Medical College in 2004 and Ph.D. degree from the University of Hong Kong in 2011. He has been a Visiting Scholar in the Medical University of Vienna and a Clinician Scientist of Yijishan Hospital of Wannan Medical College. He is currently a Professor of Nanjing Medical University and a Research Fellow of National Cancer Center Singapore.
Molecular pathology & translational medicine
Principal Investigator of several national grants, such as The National Natural Science Foundation of China (NSFC, China) and National Medical Research Council (NMRC, Singapore). His studies have been published in the leading international journals including Hepatology, Journal of Hepatology, Gut, ACS Nano, and J Biol Chem, etc.
Dr Tornesello Maria Lina is Head of Viral and Tumour Marker Section in the Molecular Biology and Viral Oncology Laboratory at the National Cancer Institute Fond Pascale in Napoli – Italy. She graduated in Biological Science from the University of Naples Federico II in 1988 and received the specialty degree in Microbiology and Virology from the School of Medicine, at the University of Naples Federico II in 1994. She is involved in the study of the cooperation of oncogenic viruses and other cofactors including host susceptibility and accumulation of genetic alterations in the carcinogenesis of virus-driven tumors.
Pathogenesis of hepatitis related liver cancer
Nabil Mohie Abdel–Hamid is a Professor of Cancer Biology and Head of Department of Biochemistry, Ex- Dean and Founder of Pharmacy College, Kafrelsheikh University, Egypt. He is the member of Higher Consulting Organization of Egyptian Scientists Council. He is the Deputy of the Director of Egyptian Association of Cancer Research. He is the Head of Drug Manufacturing Committee, Arab Union of Rights of Intellectual Property, and Arab League. He is a Member in The Arab Evaluators for Scientific Degree Promotions. He is a member in Egyptian Evaluators for Scientific Degree Promotions. His Research Interest is Cancer Biology. He is a Principal Instructor of Hepatocellular Carcinoma Research Programs. His Research goals are Early Detection and New Trends in Management of Hepatocellular carcinoma, including chemo and radio sensitization to cancer therapy. He is the Editor in Chief for American Journal of Cancer Prevention, USA and Archives in Cancer Research, Spain. He is an Editorial Board Member for Twenty International Journals. He Published Forty Six International Publications and Six Books (Including 2 international, USA and UK).
Early detection and new trends in management of hepatocellular carcinoma, including chemo and radio sensitization to cancer therapy
Toxicology; nanotechnology and food safety
Anatomical & clinical pathology; clinical research and electron microscopy; gastroentrology and liver disease
Prof. Dr. Osama Mohamed Ahmed is a Professor of Physiology at Beni-Suef University, in Beni-Suef, Egypt. Dr. Osama received his Ph. D. in Comparative Physiology (2000) at the Cairo University and his is associated as member in International Biographical Center(IBC), Cambridge, England, Winner of BSU Excellence Award 2015, Director of Research Publication Unit in Beni-Suef University.
Studies on experimentally-induced type 1 and 2 diabetes and its treatment with medicinal plants and plant constituents
1. Hepatotoxicity and anti-tumor activities
2. Experimentally-induced hypo- and hyper-thyroidism.
3. Chemically-induced carcinogenicity and the treatment of cancer with natural products and newly synthesized organic compounds
Amr Amin has completed his PhD at University of Illinois at Chicago, and received a post-doctoral training in the field of molecular genetics at the University of Pennsylvania School of Medicine. He started his academic career at UAE University where he serves now as a Full Professor of Cell Biology. Amr’s research focuses on ways to control cancer, particularly liver cancer. He published many research articles and reviews and serves as reviewer and as an editorial member of many specialized peer-reviewed journals. He is also a member of many specialized societies and the sole recipient of many scientific awards.
Biology and chemoprevention of cancer; preclinical studies; and novel plant-based anticancer drugs
Professor Pietro Andreone graduated from the University of Bologna (Italy) School of Medicine and Surgery in 1980 and completed his training in Internal Medicine attaining Fellowship in 1989. In the same year he was appointed as Assistant Professor and from 2005 as Associate Professor of Internal Medicine in the Department of Medical and Surgical Sciences at the University of Bologna. From 1991 he is the leader of a research group and has had continuous funding from several research institutions. His research field are the diseases of the liver with special interest in viral hepatitis, cirrhosis, hepatocellular carcinoma, liver immunology, liver transplantation and liver stem cells. Professor Andreone has published 193 peer reviewed publications with a h-index of 40. He has or has had several collaborations with international research groups. He is the Director of the Program for the Diagnosis and Treatment of Chronic Viral Hepatitis at the University Hospital of Bologna. He has been the principal investigator in over 70 clinical studies especially in the field of innovative therapies for hepatitis C, hepatitis B and autoimmune liver diseases.
1. Liver cirrhosis
2. Hepatocellular carcinoma
3. Liver transplantation
4. Liver immunology
5. Liver stem cells
6. Chronic hepatitis
1. Design and chemical synthesis of cytofectins (agents used in manufacture of cationic liposomes)
2. Liposome design and liposome-mediated gene and siRNA transfer into animal cells and small mammals: targeted and untargeted approaches (Nanotechnology)
3. Protein-DNA interaction and non-viral gene transfer into mammalian cells by receptor mediated endocytosis
4. Design and synthesis of reverse transcriptase inhibitors – potential antiviral agents against HIV
Dr. Bilgin Kadri Aribas, graduated from the Hacettepe University Medical School, Ankara(1978-1985) with receiving the M.D. Degree, is now the Radiologist, Associate Professor in Radiology Department of Radiology, Dr. Abdurrahman Yurtarslan Ankara Oncology Education and Research Hospital. Except being as a Editorial Board Member of Hepatoma Research, he also serves as Editorial Board Member of 7 more journals. To date, 42 of his published articles are indexed in SCI-E, SCOPUS, INDEX MEDICUS and other important databases.
Dr. Thiago Beduschi is a surgeon in Miami, Florida and is affiliated with multiple hospitals in the area, including Jackson Memorial Hospital and University of Miami Hospital. He received his medical degree from Other and has been in practice between 11-20 years. He is one of 43 doctors at Jackson Memorial Hospital and one of 57 at University of Miami Hospital who specialize in Surgery. He also speaks multiple languages, including Portuguese.
Clinical surgery; liver/GI transplantation
Stephen J. Beebe, molecular cell biologist / biochemist received his PhD in 1982 from the Medical College of Ohio, (now the Medical School at University of Toledo) in Medical Sciences (Pharmacology/ Biochemistry). He was a post-doctoral fellow at the Howard Hughes Medical Institute and Department of Molecular Physiology and Biophysics at Vanderbilt University, Nashville Tennessee. He was Fulbright Scholar at the University of Oslo, Norway and at the National Hospital and Department of Medical Biochemistry before taking a position as Assistant Professor in the Jones Institute for Reproductive Medicine and then an Associate Professor in the Department of Physiological Science and the Center for Pediatric Research at Eastern Virginia Medical School in Norfolk, Virginia. He is now a Professor at Old Dominion University in the Frank Reidy Research Center for Bioelectrics in Norfolk Virginia.
Physiological sciences; pediatric
Prof. Giulio Belli obtained his MD degree from University of Naples in 1975. He is the Head of General and HPB Surgery, Loreto Nuovo Hospital, Naples, Italy since 2000. He is Founder member of the World Association of HepatoBilairyPancreatic Association (WHBPA), Former member of the Scientific Committee of International HepatoPancreatoBiliary Association (IHPBA), Former Member of the Council of the European Hepato-Pancreato-Biliary Association (EHPBA), Founder and Member of the Council of International HepatoPancreatoBiliary Association-Italian Chapter (IT-IHPBA), etc. He serves as Editorial Board Member and Reviewer for many famous journals. Also he is author of 11 HPB book chapters, Invited Speaker in 105 National and 61 International Congress, and author of 351 pubblications.
General and vascular surgery
"Dr. Berretta completed his Master Course in Senology at European Institute of Oncology, University of Milan, Italy and PhD in Oncology from the University of Catania, School of Medicine and Surgery on Chemotherapy of advanced colorectal cancer in the elderly patients His certificates include October 2008: Geriatric Specialization, University of Catania, School of Medicine and Surgery, (marks of 70/70 cum laude), title of dissertation “Folfox2: Efficacy and safety profile in the treatment of elderly patients, affected by metastatic colorectal cancer”.
October 2001: Oncology Specialization, University of Catania, School of Medicine and Surgery, (marks of 70/70), And title of dissertation: “Soft tissue sarcomas in adults: natural history, prognostic factors and role of adjuvant chemotherapy in sarcomas of the limbs”.
May 1997: Board certification from the University of Catania, Italy.
22 July 1996: Doctor of Medicine from the University of Catania, School of Medicine and Surgery, Italy, (marks of 110/110 cum laude), title of dissertation: “Rhinoseptoplasty: advantages and limitations of the surgical techniques”. "
Dr. Alain Braillon is currently working as chief of an Alcohol Treatment Unit (Department of Medicine, Amiens, France). He received his medical degree (Amiens University), obtained a PhD (University of Paris-Diderot) and a Board Certification in Gastroenterology in 1984. He completed a chief fellowship in Hepatology and was Assistant Professor from 1984 to 1986 (Amiens University). He was post-doctoral fellow at the Department of Pharmacology and the Cardiovascular Center at the University of Iowa. He obtained a tenure position at the Institut National de la Santé et de la Recherche Médicale (French NIH) in 1987 as an Associate Director of Research (Hepatic Hemodynamics Unit, Beaujon’s hospital). He is author or co-author of more than 275 scientific publications referenced in Pubmed. His specific interests are tobacco and alcohol control.
Gastroenterology; quality and security of care
Dr. Erwin Brenndörfer is currently working as project leader at Medivir, a Swedish biotech company focused on oncology and infectious diseases. In addition, he is affiliated to the Karolinska Institute, where he is supervising students in the fields of viral hepatitis and liver immunology. He received his PhD in HCV research in 2009 from Dϋsseldorf University in Germany. After that, he was recruited to the Karolinska Institute in Sweden, where he established as independent researcher with a strong virology/oncology background.
Viral hepatitis; hepatocellular carcinoma and drug development
Leading expert in the management of liver cirrhosis; hepatocellular carcinoma, in the selection and evaluation of candidates for liver transplantation; in the post-liver transplant patient management
Gastroenterology and hepatology
Dr. Eleazar Chaib is Director of Department of Gastroenterology at University of Sao Paulo in Brazil. Dr. Chaib received his Ph.D from University of Sao Paulo School of Medicine. He is a member of the Transplantation Society, Brazilian Society of Videolaparoscopy, International Hepato - Pancreato Biliary Association. He is a Fellow of the Royal College of Surgeons - England (FRCS), Fellow of the Royal Society of Medicine - England (FRSM) and Member of American Association of Clinical Anatomist (AACA). His Research interests include Hepato - Pancreato - Biliary Surgery and Anatomy, Liver and Pancreas Transplantation.
Hepato-pancreato-biliary surgery and anatomy; liver and pancreas transplantation
1. Embryonic stem cells
2. Liver regeneration
3. Liver transplantation.
4. Liver stem cells
President Chen obtained PhD in 1999 at Kaohsiung Medical University. Currently teaches in Fooyin University, as most young is also the most senior professors and deans. The past 10 years, he has his scientific interests focused on life-threatening diseases, including traditional spices used for gastrointestinal cancer-related topics.
Analysis in recent years major active ingredients such as ginger, pepper and garlic, used in gastrointestinal cancer, anti-inflammatory, antioxidant, antiparasitic, and other topics.
President Chen specializes in isolation, purification and structural analysis of active components of plants. President Chen directed against active constituents of oral cancer, liver cancer, and rectal cancer. President Chen was just over 40 years old, but his work has more than 170 papers, Taiwan one of the young talents.
Traditional spices used for gastrointestinal cancer-related topics; ginger; pepper and garlic; used in gastrointestinal cancer; anti-inflammatory, antioxidant; antiparasitic; isolation; purification and structural analysis of active components of plants; oral cancer; liver cancer; and rectal cancer
Surgery and related biology in digestive tract cancers including liver cancer; gastric cancer; colorectal cancer
1. molecular biology of hepatitis B virus and hepatitis C virus
2. molecular mechanisms of hepatocarcinogenesis
3. functional relationship of hepatic metabolism and liver cancer
1. Extensive experience in managing all areas of complicated hepatobiliary, pancreatic diseases, deceased donor and living donor liver transplantation (including most technically demanding major vascular resection in HBP surgery, in-situ splitting and sequential liver transplantations)
2. Extensive experience in managing complex surgical problems in conjunction with other procedures (e.g. colectomy with synchronous liver resection)
3. Extensive experience in supervising different levels of surgeons
Gas chromatography; gas chromatography associated with mass spectrometry; NMR; IR spectrophotometers; spectroscopy UV; HPLC
Dr. Dai is a Professor of Department of Oncology, the Second Affiliated Hospital, Xi'an Jiaotong University. His research has been focused on anticancer and pharmacological properties of natural compounds. He obtained a PhD and Master’s degree from Xi'an Jiaotong University, China. Dr. Dai has published more than 100 peer-reviewed articles. He also has been on the editorial board of many international journals.
Anticancer and pharmacological properties of natural compounds
Dr. David graduate at Medical Sciences School of Santa Casa in São Paulo in 1993. He worked as a MD at Aeronautical Medical Hospital of São Paulo in 1994. After that, he did General Surgery residency (1995-1996) and GI Surgery residency (1997-1998 ), specializing in abdominal organ transplantation (1999-2001). Also he did his Master (2001-2003) in Medicine at Medical Sciences School of Santa Casa de São Paulo and his Doctorate at the University of Miami School of Medical Sciences of Santa Casa of São Paulo in small bowel transplantation (2004-2007). He did postdoctorade with CNPq / Einstein in experimental intestinal and multivisceral transplantation. He worked as a Surgeon at Transplantation Program of Hospital Israelita Albert Einstein from August, 2008 to July, 2010. Nowadays he is an Attending Physician in GI Transplantation Prograam of the Department of Gastroenterology, Clinics Hospital of University of São Paulo. He works in GI Surgery, liver, pancreas, small intestine and multivisceral transplantation. Titular member of the Brazilian College of Surgeons, member of the American Society of Transplant Surgeons and the Department of Pediatric Transplantation of the Brazilian Association of Organ Transplantation. Dr. Andre is the Research Coordinator of Liver and Portal Hypertension Program at Santa Casa of São Paulo and Coordinator of the Nucleus of Gastro and responsible for the technical program of Liver Transplantation, Pancreas-Kidney and Pancreas of Hospital Samaritano of São Paulo.
Liver transplantation; GI surgery; liver; pancreas; small intestine and multivisceral transplantation
Dr. Di Fazio graduated as Biologist at University of Palermo in 2004. He worked as Research Fellow at Department of Pathology & Experimental and Clinical Medicine at University of Udine (2004/2005). He achieved his doctorate in Experimental Oncobiology (2007) at Department of Biochemical Sciences at University of Palermo where he started his PostDoc career. He was awarded of a fellowship from University of Palermo and a Short Term Fellowship from EASL. He moved to University of Marburg (2009) being awarded with a Sheila Sherlock PostDoc Fellowship from the European Association for the Study of the Liver (EASL). Since 2011, he is a permanent scientist at Marburg University at the Department of Visceral Thoracic and Vascular Surgery studying liver, thyroid and pancreas pathogenesis, apoptosis, ER stress and autophagy.
Liver fibrosis; cirrhosis and cancer; canonical and alternative mechanisms of cell death (ER stress, autophagy) and miRNAs activity in tumors
Dr Shiwei Duan completed his Ph.D.in Human Genetics in Department of Molecular Cell Biology from Shanghai Jiao Tong University, China. He has done MS in the field of Applied Biochemistry. From 2011 to present he is working as Professor, School of Medicine, Ningbo University.
Epigenomics and pharmacogenomics in anti-cancer chemotherapy (Epi); genetics and (epi)genomics for cancers and complex diseases
Autoimmunity in hepatology Chronic viral hepatitis; non alcoholic steatohepatitis; role of adipokines in chronic liver diseases; alterations of sexuality in patients with liver disease; liver disease in the elderly; metabolic syndrome; nutritional disorders in the patient with metabolic disorders
Dr. Ebert earned his doctoral degree in Berlin (2000) and acquired his postdoctoral teaching qualification (habilitation) at TUM (2010). Following clinical work at the University Hospital in Bonn and a German Research Foundation (DFG) funded postdoctoral research fellowship at the Mount Sinai School of Medicine in New York he returned to Germany in 2005 to conduct research and clinical work in the Department of Internal Medicine and Outpatient Care (II. Medizinische Klinik) at Klinikum rechts der Isar.
1. Translational gastrointestinal oncology / hepatology
2. Preclinical development of oncolytic virotherapy of gastrointestinal cancers using recombinant negative-strand RNA viral vectors
3. Multimodal functional imaging for selection, monitoring and individualization of gastrointestinal cancer therapies
Dr. Pinar Erkekoglu is graduated from Hacettepe University Faculty of Pharmacy (BS) and Anadolu University Public Relations School (BS). She completed a part her PhD studies in Grenoble, France in Universite Joseph Fourier and CEA/INAC/LAN after receiving full scholarship from both European Union Erasmus Scholarship Program and from CEA. She worked as a post-doc and visiting associate in MIT (Massachusetts Institute of Technology) Biological Engineering Department between 2011 and 2012. Her main interests are the reproductive disorders, and oxidative stress induced by endocrine disrupting chemicals, particularly by phthalates, the protective role of selenium against oxidative stress and the toxic effects of aromatic amines. She has published more than 90 papers in national and international peer-reviewed journals and is currently working as an associate professor in Hacettepe University Faculty of Pharmacy Department of Pharmaceutical Toxicology. She is a European Registered Toxicologist (ERT) since 2014
Toxicology studies; male reproductive disorders
Dr. Lynn Feun is a medical oncologist in Miami, Florida and is affiliated with multiple hospitals in the area, including Jackson Memorial Hospital and Miami Veterans Affairs Healthcare System. He received his medical degree from Wayne State University School of Medicine and has been in practice for more than 20 years. Dr. Feun accepts several types of health insurance, listed below. He is one of 21 doctors at Jackson Memorial Hospital and one of 14 at Miami Veterans Affairs Healthcare System who specialize in Medical Oncology.
Developmental therapeutics; medicine; oncology
Marcelo Augusto Fontenelle Ribeiro Junior graduate at Ciências Médicas from Pontifícia Universidade Católica de São Paulo (1992), master's at Surgery from Universidade Federal de São Paulo (1997) and ph.d. at Surgery from Universidade Federal de São Paulo (2000). Has experience in Medicine, focusing on Experimental Surgery, acting on the following subjects: carcinoma hepatocelular, radioablação, trauma, pneumoperitoneo and métodos ablativos
Carcinoma hepatocelular, radioablação; trauma; pneumoperitoneo and métodos ablativos
Samuel French is a liver pathologist and scientist who has been on faculty at the UCLA Department of Pathology since 2002. Dr. French earned his B.A. in Biophysics at U.C. Berkeley and M.D. and Ph.D. in Biochemistry at the University of Pittsburgh. He completed his residency in Pathology at UCLA as well as fellowship in gastrointestinal/liver pathology. He was a postdoctoral fellow at ucla where he worked on lymphomagenesis. He is a recipien of the Boyer-Parvin Postdoctoral Recognition Award and Cure Named New Investigator Award. Dr. French is currently developing a proteomic based program to study the developoment of liver cancer from hepatitis C viral infection.
Anatomic pathology; surgical pathology
1. Ischemic-reperfusion injury in transplantation
2. Pancreatic islet transplantation
3. Assessment of primary and secondary cancer of the liver
4. Information technologies applied to medicine
Dr. Geller is the Richard L. Simmons Professor of Surgery at the University of Pittsburgh School of Medicine, and Director of the UPMC Liver Cancer Center. As a hepatobiliary Surgical Oncologist, his clinical interests center on the evaluation and management of patients with liver cancers.
He has pioneered laparoscopic liver resection surgery. Dr. Geller and his team have performed more than 800 of these cases. Most of these patients are discharged home on the second post-operative day with 4-5 bandaid-sized incisions. He also specializes in performing laparoscopic radiofrequency ablations of liver tumors.
Dr. Geller is a member of many professional and scientific societies including the Society of Surgical Oncology, Society of University Surgeons, and the American Society of Transplant Surgeons.
Dr. Geller has published 280 scientific papers and chapters. He is often a guest lecturer speaking on the management of liver tumors and has presented at more than 360 meetings or seminars. He has active research grants from the NIH, and is also the Principal Investigator on Industry-sponsored clinical trials for liver cancer.
Antonio Giorgio was graduated in Federico II University Naples, Italy. Founder and Director of Interventional Ultrasound Unit D. Cotugno” Hospital - Naples, Italy. His clinical and research activity is mainly focused on the ultrasound of liver diseases and ultrasound guided percutaneous treatment of HCC on cirrhosis, hydatid, abdominal abscesses and metastatic tumors of the liver and, more recently, intrahepatic cholangiocarcinoma.
He is author of more than 350 scientific publications.
He is author of many chapters in texts prepared by other authors, in general about ultrasound diagnostics (some of these are: Italian Treaty on Ultrasound - 2000, Atlas of Abdominal Ultrasound – 2003, Ultrasound in Internal Medicine - 2008).
Ultrasound diagnostics in liver diseases and the ultrasound guided percutaneous treatment of HCC on cirrhosis; hydatid and simple liver cysts; abdominal abscesses and metastatic tumors of the liver and, more recently; intrahepatic cholangiocarcinoma
Medical professor Yong-Song Guan is male, advisor of medical masters, mentor of medical doctorate and post-doctoral students. He is now a teacher in Sichuan University, an expert physician in Department of Oncology and Radiology of West China Hospital, and a post-retention member of State Key Laboratory of Biotherapy. He has been invited to serve as a member of the editorial board or reviewers of more than a dozen of medical journals home and abroad (many of the journals are indexed by SCI or MEDLINE). He has started his interventional career since 1986, and gained his experience in interventional diagnosis and management of more than 40,000 cases. He is good at the diagnosis and treatment of various difficult and stubborn diseases. He has been granted currently several research projects and fundations. He has been awarded several prizes, including Science and Technology Progress, 4 by Sichuan province government, one by Sichuan hygiene hall, 2 by Chengdu municipal government, and 7 excellent publication prizes by the province and municipality.
Gastroenterology and Hepatology
3. 3D imaging, X-ray computer
5. cancer gene therapy
6. carcinogenesis models
7. Diagnostic imaging
8. interventional therapy
9. Medical problem solving
10. Molecular Imaging
Professor Sen-Yung Hsieh earned his MD degree from the National Yang Ming University in 1983, and obtained his PhD in Molecular Virology and Pathology from University of Pennsylvania in 1991. He received his clinical training in internal medicine, and subsequent a specialty in hepatogastroenterology in Chang Gung Memorial Hospital, Linko, Taiwan.
He initially focused on the molecular virology and epidemiology of human hepatitis viruses. His team for the first time identified the zoonotic transmission of hepatitis E virus from swine to humans in 1998, which was later found in other wild and domestic animals as natural reservoirs for sporadic hepatitis E in Japan and western countries. Currently, Dr. Hsieh is interested in elucidation the molecular mechanisms involving in carcinogenesis of human hepatoma. By integration of both functional genomics and proteomics approaches, he has identified novel oncogenes, tumor suppressor genes, and pathways that play significant roles in oncogenesis of human hepatoma. His works have been published in J Virology, Nucleic Acid Res, PNAS, Cancer Research, Oncogene, Proteomics, J Proteome Res, Mol Cell Proteomics, J Hepatology, and Hepatology.
1. Gastroenterology and hepatobiliary diseases
2. Hepatitis and hepatoma
3. The molecular mechanisms of hepatocellular carcinogenesis using the molecular and cellular biology, genomics and proteomics approaches.
4. Molecular virology and epidemiology of human hepatitis viruses
5. Hepatocellular carcinoma: carcinogenesis mechanisms, diagnosis, and treatments Functional genomics for novel genes and pathways implicated in hepatocellular carcinogenesis
Jian Huang currently works as Prof at Liver Research Center, Experimental Center, Beijing Friendship Hospital, Capital Medical University. He worked as a postdoctoral fellow at Section of molecular pathology, International Agency for Research on Cancer (IARC), Lyon, France during the period of 2006 to 2009, and served as associate professor at Beijing Institute of Radiation Medicine, Beijing, China from 2001 to 2006. His research activities mainly focus on the genomics and genetics of liver diseases such as liver cancer and metabolic liver diseases.
Research on the role of geneticc and genomic alterations in the pathogenesisi of liver cancer; screening of serological markers for early diagnosis of liver cancer
Dr. Muhammad Idrees obtained Ph. D. in Molecular Virology and worked for his post-doctoral research at DVH-CDC Atlanta. Currently he is the Director of Centre for Applied Molecular Biology, a premier Molecular Biology organization. He is also Head Division of Molecular Virology. His contribution in Molecular Virology has been recognized at home and abroad and his research work has been published in 107 peer reviewed research papers in international scientific journals with an overall impact factor of more than 200 of citation of more than 1300. He is the editor of several Internal Scientific Journals.
Basic collaborative research involving virus-host interactions in host pathogenesis; viral transmission; viral persistence; various immune responses and antiviral resistance associated with hepatitis C virus and hepatitis B virus infections with national and international research institutes/hospitals
Toru Ishikawa, Ph D, M.D., General Manager of Gastroenterology, Saiseikai Niigata Daini Hospital from 2008 to now. From 1992 to 1993, Ishikawa was a Resident in the Niigata University Hospital, Niigata, Japan. From 1993 to 1994, Ishikawa was a Resident in the Sinrakuen Hospital, Niigata, Japan. From 1994 to 1995, Ishikawa was a medical Staff in the Saiseikai Niigata Daini Hospital, Niigata, Japan. From 1995 to 2002, Ishikawa was a Resident in the the Third Department of Internal Medicine in the Niigata University Hospital, Niigata, Japan. From 2002 to 2007, Ishikawa was a Head Doctor of Gastroenterology, Saiseikai Niigata Daini Hospital.
Hepatocellular carcinoma; portal hypertension; hepatitis
Osamu Itano ius currently working as lecturer at medical department, Keio University, Japan. He served as assistant professor at Keio University School of Medicine from 2010- 2012. He has extended his/her valuable service as a lecturer has been a recipient of many award and grants. His international experience includes various programs, contributions and participation in different countries for diverse fields of study. His research interests as a lecturer reflect in his wide range of publications in various national and international journals.
Cancer care and research, advanced laparoscopic surgery in hepatobiliary/pancreas areas; transplantation
Digestive surgery; endoscopic surgery; medical ultrasound
Molecular targets and therapeutics for hepatobiliary cancers; innovative techniques in hepatobiliary surgery and perioperative care; liver transplantation and bio-artificial liver
Dr. Hironori Kaneko is a chairman and professor, Department of Surgery, School of Medicine, Toho University at present. Dr.Kaneko graduated from Toho University, School of Medicine and completed his PhD in 1987. He did surgical training at Hartford Hospital in Connecticut for 3 years. He holds numerous professional appointments as described below.Dr. Kaneko is the Fellow of the American College of Surgeons, Editorial Board Member of Journal of Hepato-Bliary-Pancreatic Science, National Editor of International Association of Surgeons, Gstroenterologists and Oncologists, Member of International Society of Surgery, International Hepato Biliary Pancreat society, etc. and the councilor of many Japanese surgical societies including the president of Japanese Liver Study Group of Endoscopic Surgery. He is actively involved in both experimentally and clinical research, has published numerous scientific publication, and serves on academic advisory board. He is initially performed laparoscopic surgery to patient with HCC since 1993 and one of world leader of laparoscopic liver surgery.
HPB surgery and endoscopic surgery; ischemia-reperfusion injury; cytokine in suergical stress
The Dr Kayaalp was graduated as a Doctor of Medicine in 1989 from Hacettepe University.
The Dr Kayaalp's surgical education included Ankara Numune Hospital, General Surgery Department and Yuksek Ihtisas Hospital Department of Gastrointestinal Surgery. He has been studying at Inonu University, Department of General Surgery since 2005. Liver surgery is one of my favorite topics. He has several national and international studies about liver surgery. He is a member of Turkish Society of Surgery, Turkish Hepatobiliary Surgery Association, Turkish Society of Gastroenterology and IASGO (International Association of Surgeons Gastroenterologists and Oncologists).
General surgery; gastrointestinal surgery; gastrointestinal and hepato-biliary-pancreatic surgery
Dr. Dean Y Kim is a General Surgery Specialist in Detroit, Michigan. He graduated with honors from Columbia University College of Physicians and Surgeons in 1994. Having more than 22 years of diverse experiences, especially in GENERAL SURGERY, Dr. Dean Y Kim affiliates with many hospitals including Henry Ford Hospital, Hurley Medical Center, Children's Hospital Of Michigan, and cooperates with other doctors and specialists in many medical groups including Henry Ford Health System, Vhs Physicians of Michigan. Call Dr. Dean Y Kim on phone number (313) 916-2436 for more information and advises or to book an appointment.
Kidney and pancreas; transplantation; transplantation and hepatobiliary surgery
Image-guided interventional oncology; percutaneous (biopsies and ablations) and transcatheter therapies (chemoembolization, embolization and Y90) for primary and metastatic liver cancer; MRI-guided interventions and high intensity focused ultrasound ablations; translational and clinical research with development of new novel minimally invasive oncologic therapy with high impact in the clinical arena
Translational angiogenesis research Biopharmaceuticals; RNA mediated and other novel therapeutic approaches; heart failure; RNA based biomarkers
Chronic C hepatitis; treatment-naïve and experienced patients; prospective; international non-interventional cohort studies; phasys III- IV studies; (peginterferon-alfa2a and b - ribavirin, PegIFN-ribavirin-boceprevir)
1. Biological role of alpha fetoprotein in carcinogenesis
2. Expression and regulation of mu opioid receptor gene
He is a professor of biomaterials at School of Materials Science and Engineering, Southwest Jiaotong University. His current research interests are biomaterials design, controlled drug release for cancer treatment and tissue regeneration.
He received his B.A. in 1991 from Fudan University, M.Sc. in Polymer Chemistry and Physics in 1994 from Chengdu Institute of Organic Chemistry, Chinese Academy of Sciences, and Ph.D. in Chemistry in 1999 from Institute of Chemistry, Chinese Academy of Sciences. He was a postdoctoral fellow in College of Pharmacy, Ohio State University (2000-2002) and Department of Biomedical Engineering, Johns Hopkins University (2002-2004).
He has over 100 publications to his credit that include research papers, reviews, and conference proceedings. He is a member of Controlled Release Society (CRS), Tissue Engineering and Regenerative Medicine International Society (TERMIS), and Chinese Committee of Biomaterials (CCBM). He is also an Editorial Board Member of Journal of Clinical and Laboratory Investigation Updates (JCLIU) and Journal of Biochemistry and Molecular Biology Research (JBMBR).
Biomaterials design; controlled drug release for cancer treatment and tissue regeneration
1. Gastrointestinal cancers
2. Organ transplantation
3. Minimally invasive surgery
4. Environmental medicine
5. Cancer genetics
6. Anticancer drugs
7. Translational Medicine
Anticancer and antimetastatic effects of 3-polyunsaturated fatty acid; inflamation and cancer (PGE2 and Wnt signaling) including hepatoma Regulation of metastasis-specific gene; development of antimetastatic and antiangiogenic proteins
Genomics; proteomics and systems biology of HCC including biomarker discovery and validation; and personalized medicine
Professor Lin received his M.D. education at Taipei Medical University and specialty training at Internal Medicine, Gastroenterology and Hepatology in Chang Gung Memorial Hospital, Linkou Medical Center. Thereafter, Professor Lin was continuing his immunology research and was subsequently awarded PhD degree by the Oxford University. Professor Lin’s clinical and research interests focus on the both immunological and clinical aspects of chronic hepatitis and tumour. He serves as a reviewer for many international journals and has published many research articles including Nature Immunology, Cancer Research, Clinical Cancer Research, Journal of Immunology, Journal of Hepatology, American Journal of Gastroenterology and so on.
1. Immune mechanisms of immune regulation: using mice model to explore the suppression mechanisms of different regulatory immune cells, including regulatory T cells, tolerogenic dendritic cells; tumor-associated macrophage and MDSC
2. Immune regulation in tumor immunotherapy: using mice model to develop strategies of tumor immunotherapy, especially to block the inhibition effect of immune regulation.
3. Immune regulation in acute liver injury: using mice model to explore the immune derangement in acute liver injury and to develop possible treatment strategies
4. Translational Studies: Immune regulation in chronic viral hepatitis, liver cirrhosis, acute liver failure and cancer: using human studies to understand the impact of immune regulation on the disease progression and treatment outcome. The aim is to develop effective immune therapy and to develop useful immunometer for predict the disease progression.
5. Clinical studies: Disease characteristics and treatment responses for chronic hepatitis C, chronic hepatitis B, liver cirrhosis and hepatoma. An immunological concept is the main underlying reasoning to approach these diseases
1. The role of thyroid hormone receptor in human hepatocellular carcinoma
2. The role of long-non-coding/miRNA RNA in human hepatocellular carcinoma
3. The clinical significance of aberrantly express genes in human hepatocellular carcinoma
4. The role of autophagy in liver carcinogenesis
Medical pathology & lab medicine; pharmacology; toxicology & therapeutics
Dr. Romaric Loffroy, M.D., Ph.D., is Professor of interventional radiology currently doing research at the University of Dijon School of Medicine. Originally from Dijon, France, Dr. Loffroy obtained his medical degree from the University of Burgundy, Dijon, France in 2001 and then perceived his residency in radiology at the same University which he completed in 2006. Thereafter, his special interest in the field of interventional radiology led him to do a clinical fellowship in interventional radiology at the department of vascular and interventional radiology at the University Hospital in Dijon, France. His field of expertise is in interventional radiology, especially in embolization techniques with particular interest in gastrointestinal bleeding as well as peripheral vascular diseases. He has been at the fore front of newer and more successful techniques in embolization of gastrointestinal bleeders which reduce the failure rate as well as the necessity of reinterventions. Dr. Loffroy’s keen interest in the field of research in interventional oncology brought him to the research center in the department of interventional radiology at the prestigious Johns Hopkins Medical Hospital in Baltimore as a postdoctoral research fellow in 2009. Dr. Loffroy is currently doing research in improving tumor imaging quality in interventional radiology and working towards newer interventional radiology therapies for liver cancer. Dr. Loffroy has published numerous SCI journal papers and book chapters, edited/reviewed for many academic journals, coordinated/participated in several international/national projects, served as an evaluation expert for organizations such as French Society of Radiology (SFR) and High Authority of Health (HAS).
Diagnostic imaging: US; CT; MRI; angiography; liver disease Therapeutic imaging: image-guided therapy; vascular and oncologic interventional radiology; visceral embolization; radiofrequency
Dr. Giuseppe Lombardi graduated in medicine and surgery at Padua University, Italy in 2004. Then received his MD specialization in medical oncology with full marks and Laude, Padua University in 2008, and PhD specialization in oncology, Padua University in 2012. Now he is the a medical oncologist at Clinical and Experimental Department, Medical Oncology 1, Veneto Institute of Oncology- IRCCS, in Padua. He has more than 80 publications in PubMed.
Clinical and Transaltional research for Hepatocellular Carcinoma and Brain Tumors
Francesco Loria born on 07 August 1965 in Reggio Calabria, Italy, medical doctor, specialized in Radiology(1994, Genoa University, Italy) and in Radiation Oncology (1998 Messina University, italy), with titles recognized by FMH of Berna (Swiss 2011).
My task is to effect US, CEUS, TC and MRI, more specifically abdominal radiology and musle-skeleltal radiology.
I have published till now 133 reports in the most important medical journal of the sector ( Radiology, AJR, BJR, Eur Radiol, Radiol Medi, Ann of Hepatology, Anticancer Research, Updates in Surgery ecc)
I took part as relator in 50 national and international congresses of Radiology and Surgery.
In march 1995 I win the contest of the European Congress of Radiology with the presentation as one of five best research reserved to under 35 radiologist with the following presentation: MR ENHANCEMENT OF ASCITES AFTER INTRAVENOUS ADMINISTRATION OF GD-DTPA.
Diagnostic radiology; radiology oncology
Signal transduction; cell cycle; medicinal chemistry; cancer molecular medicine; alzheimer's disease
Dr. Majumdar, PhD, received his doctoral degree specializing in Cell and Molecular Biology from the School of Biomedical Sciences at Kent State University, Ohio on 2008. In his doctoral research, he made two key discoveries which include determining the mechanism of action of the anti-angiogenic drug fumagillin at cellular level and identifying novel tumor suppressor function of MetAP2/P67 which was a known regulator of protein synthesis machinery. He was the recipient of the “Excellence in Research” and “Research Grant Award” at Kent State University. Following his doctoral degree, he joined as a postdoctoral fellow in the department of Pharmacology at Case Western Reserve University, Ohio, where he worked on the post-translational modification of retinoic acid transporter protein, cellular retinoic acid binding protein-II(CRABP-II). On 2011, he joined as a postdoctoral fellow in the Department of Gastroenterology, Hepatology and Nutrition at the University of Texas MD Anderson Cancer Center. Currently, as a Senior Research Scientist he is working on the mechanistic role of carcinoembryonic antigen(CEA), a widely used marker for determining the recurrence of colorectal cancer (CRC), in promoting CRC metastasis. He received the “Poster of Distinction” award in the “Digestive Disease Week” annual conference on 2013.
Cell & molecular biologist with proven expertise in areas such as preclinical and translational research on cancer biology; cell & molecular biology; oncology; cell proliferation process development for primary; transformed and stem cells; tumor metabolism; discovery of novel tumor suppressor; gene therapy; cancer cell signaling; live cell imaging, identification of new drug target; elucidation of novel targeted therapy as well as translational research focusing on identification of novel prognostic markers for early detection of cancer progression
Prof. Mahmoud Mansour received his pharmacy degree from the Al-Azhar University Cairo-Egypt, in 1984, and his Ph.D. degree in clinical Biochemistry from the Karolinska Institute, Stockholm Sweden in 1992. From 1996 to 2016, he joined the King Saud University. As a Fellow, he contributed significantly to defining some aspects of the molecular biology of tissue injury and induction of lever toxicity and renal toxicity, with particular focus on role of antioxidant in prevention and treatment of different toxic effects. In addition, he contributed significantly to develop a new strategy for those tumors especially liver. His research has shown that proteasome inhibitor especially irreversible part plays an important role in preventing pathogenic role carcinogenesis of liver by metastatic tumors. He then moved to King Saud bin Abdulaziz University for Health Science, where he continued to work on the pathogenesis of cancer and on issues concerning the cellular and molecular mechanisms of cancer biology and the metastatic process. He conducted studies on liver cancer using gankyrin role in liver cancer.
1. Leukotrienes: synthesis; quantitation and biological effect
2. Lipoxins: synthesis; quantitation and biological effects
3. Monohydroxy acids (Mono-HETEs): generation and quatitation
4. Oxidative damage and free radicals generations
5. Antioxidants as cancer preventive agents
6. Tumor markers in the early diagnosis of cancer
7. Oncogenic transformation and molecular biology
8. Magnetic cell sorting of the bone marrow cells
9. Biochemical changes in aging
Experimental hepatology and drug targeting; biomedical investigation in liver and gastrointestinal diseases
Antonio Mazzocca received his Medical degree from the University of Bari, Italy, in 1994, and his Ph.D. degree in clinical pathophysiology from the University of Florence, Italy, in 2001. From 2001 to 2004, he joined the Division of Cancer Biology and Angiogenesis of Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA, for the postdoctoral studies. As a Fellow, he contributed significantly to defining some aspects of the molecular biology of metastasis, with particular focus on those tumors that preferentially metastasize to the liver (i.e., colon, breast, and melanoma). His work at Harvard culminated in the identification and functional characterization of a soluble protein termed ADAM9-S (a molecule belonging to the family of ADAMs). His research has shown that this protein plays a pathogenic role in facilitating the infiltration and colonization of liver by metastatic tumors. He then moved to the Department of Pathology at the Medical Center of Vanderbilt University, Nashville, USA, where he continued to work on the pathogenesis of cancer and on issues concerning the cellular and molecular mechanisms of cancer biology and the metastatic process. He became an Investigator in 2009 at the Department of Emergency and Organ Transplantation, University of Bari Medical School. In this position, he conducted studies on liver cancer. In particular, Dr. Mazzocca’s research focuses on the study of pathogenic mechanisms involved in the remodeling of ECM during hepatocarcinogenesis, stromal tumor interactions, and cancer.
Primary and secondary liver tumors:
1. pathogenesis of hepatocellular
carcinoma (tumor-stromal interactions, invasion and metastasis) 2. the role of the tumor
microenvironment in the development and growth of liver metastasis. Identification of molecular therapeutic targets and development of new drugs in liver cancer 3. tumor migration; invasion; and metastasis in liver primary cancer
4. role of the tumor microenvironment in liver metastasis therapeutic cancer targets in liver metastasis
Dr. Yoshiaki Mizuguchi is currently Assistant professor of Surgery at the Nippon Medical School Hospital in Japan. He is living in Shibuya, a central town of Tokyo and he loves swimming and Sumo wrestling. Besides working on a general/hepatobiliary surgery (especially on a laparoscopic surgery) for over a decade - he is nowadays doing EUS-FNA examination as well as therapeutic application. In addition, he possess a research profile too. Dr. Mizuguchi’s recent research interests are exploring the mechanisms of the regulation of microRNA transcription in hepatobiliary cancer. He made a land mark achievement in this field when he recently reported the association of miR-200 family and EMT(epithelial-mesenchymal transition). One of his major achievements other than microRNA is the report and Japanese patent in which he demonstrated that Silencing with RNA interference for Transforming beta receptor 2 can control acute liver injury.
Hepato-biliary-pancreatic surgery; laparoscopic surgery
Prof. Zenichi Morise graduated from Keio University and got his M.D. in 1987, and obtained Ph.D. in Medicine in the same university in 1995. He was post-doctoral research fellow of Louisiana State University Medical Center between 1995 and 1998. He has been professor in the Department of Surgery, Fujita Health University School of Medicine since 2010. He is certified from Japanese Board of Cancer Therapy, Japanese Surgical Society, Japanese Society of Gastroenterological Surgery, Japanese Society of Hepato-Biliary-Pancreatic Surgery and Japanese Society for Surgical Metabolism and Nutrition. Besides, he is editorial board member of World Journal of Gastrointestinal Surgery, World Journal of Gastroenterology, Frontiers in Surgery, Hepatoma Research, and Fujita Medical Journal. He is also member of American College of Surgeons, American Gastroenterological Association, Society for Surgery of the Alimentary Tract (USA), International Society of Surgery, International Society of Digestive Surgery, International Hepato-Pancreato-Biliary Association, etc.
Medicine; surgery; hepato-biliary surgery; laparoscopic surgery; liver disease
Laboratory medicine; blood system research
Hepato-bilio-pancreatic surgery; organ harvesting and liver and kidney transplantations
T. B. Ng obtained his Ph.D. degree from the Memorial University of Newfoundland in Canada. He pursued postdoctoral training at the University of California in San Francisco. He is currently a professor of biochemistry at the School of Biomedical Sciences, Faculty of Medicine, the Chinese University of Hong Kong, Hong Kong, China. His research interests encompass biologically active proteins and peptides of animal, plant, fungal and bacterial origins; polysaccharide-peptide complexe; polysaccharides; melatonin and derivatives; and natural products. He has supervised a large number of postdoctoral fellows and graduate students.He has published over five hundred papers in international journals and a number of book chapters.Some of these papers are about leguminous lectins, antifungal proteins, ribosome inactivating proteins, protease inhibitors, and peroxidases. He serves as the editorial board memeber of several journals including International Journal of Peptides, Journal of Biochemistry and Molecular Biology in the Post Genomic Era,and Frontiers in Cellulose Biotechnology. He has reviewed research grant applications and manuscripts submitted to various journals for publications.
1. proteins and peptides of human, plant, bacterial and fungal origins with antifungal, antibacterial and antiviral activities such as defensins, cathelicidin and lactoferrin and their mechanisms of action; many novel proteins and peptides were discovered during the course of investigation
2. isolation and characterization of enzymes of human, plant, bacterial and fungal origins including proteases, laccases, ribonucleases, deoxyribonucleases, phytases, cellulases, superoxide dismutases, peroxidases and lysozyme
3. isolation and characterization of various bovine milk proteins;several novel proteins were discovered during the course of investigation
4. proteins and peptides with anticancer activity in tumor-bearing animals, antiproliferative activity toward cancer cells and immunomodulatory activity such as lectins, ribosome inactivating proteins, ribonucleases, protease inhibitors, defensins, and cathelicidin and their mechanisms of action
5. roles of the receptors of the hormones melatonin and leptin in the etiology of adolescent idiopathic scoliosis; biological activities of the pineal hormone melatonin and its biosynthetic relatives
6. pharmacological activities such as antioxidant, antidiabetic, anticancer, and steroidogenic activities of medicinal plants including American ginseng, Chinese ginseng, sanchi ginseng, Codonopsis pilosula, bitter gourd, Trichosanthes, yam, and Dendrobium, herbal formulas such as Erxian decoction and Tian Xian liquid, and medicinal mushrooms such as Ganoderma, Coriolus versicolor, and Cordyceps
Dr. Yong Peng is a Professor in the Department of Throracic Surgery, State Key Laboratory of Biotherapy / Collaborative Innovation Center for Biotherapy, West China Hospital, Sichuan University, China. Dr. Peng got his Ph.D. degree at Sichuan University, China, and moved to the College of Medicine, the Ohio State University, USA, for his postdoc training. Then Dr. Peng worked at Columbia University Medical Center as Associate Research Scientist, and worked in Prof. Carlo Croce’s research team at the Ohio State University Comprehensive Cancer Center as Research Scientist with Principle Investigator status. Before he joined in Sichuan University as a faculty member, Dr. Peng has ever worked in Prof. Napoleone Ferrara’ research team in the Moores Cancer Center at University of California, San Diego. Dr. Peng has extensive research experience in molecular biology, biochemistry and oncology, and his research interests are mainly on non-coding RNAs in tumorigenesis. Prof. Peng has published many papers in international peer-reviewed journals including Cancer Cell, Molecular Cell, PNAS, Nature Communication, Blood, Leukemia, J Natl Cancer Inst., and JBC.
Elucidating the biogenesis and their role of non-coding RNAs (including microRNAs and long non-coding RNAs) in tumorigenesis. Particularly, we are interested in the following areas.
1) Identify non-coding RNA species involved in fibrosis, cirrhosis and tumorigenesis using high-throughput sequencing and computational analyses.
2) Explore their biogenesis and role of non-coding RNAs in fibrosis, cirrhosis and tumorigenesis with molecular/cell biological and biochemical approaches.
3) Dissect the regulatory mechanisms of particular lncRNAs in tumorigenesis.
4) Investigate the potential of non-coding RNAs as diagnostic and prognostic biomarkers.
Dr. Raza graduated from the Sind Med Coll, Univ of Karachi, Karachi, Pakistan in 1982. She works in Loma Linda, CA and 1 other location and specializes in Anatomic Pathology & Clinical Pathology and Cytopathology. Dr. Raza is affiliated with Loma Linda University Medical Center, Loma Linda University Medical East and Loma Linda University Surgical Hospital.
Anatomic pathology & clinical pathology;surgical pathology; cytopathology
Dr. Roomi earned a doctorate degree in Biochemical Toxicology from University of Surrey, England, and is a Fellow of American College of Nutrition (FACN). He is certified by the American Board of Toxicology (DABT) and American College of Nutrition (CNS). Dr. Roomi worked at the Linus Pauling Institute in Palo Alto, California for five years before joining the Dr. Rath research Institute as a Senior Research Scientist in 2000. His research interests include cancer, drug metabolism, environmental and occupational toxicology, organic synthesis, the molecular mechanism of toxicology and free radical and oxidative damage. Dr. Roomi has published over 200 papers in international journals, and has presented at over 200 national and international meetings, written chapters in book and author of several popular articles. He is a member of American Association of Cancer Research (AACR), the Federation of American Society of Experimental Biology (FASEB). The Society of Toxicology (SOT) and the American Society of Clinical Patholgy (ASCP).
1. Chemical carcinogenesis
2. Cancer treatment and chemoprevention
3. Environmental and occupational toxicology
4. Drug metabolism
5. Molecular mechanism of toxicity
6. Free radical and oxidative damage
7. Organic synthesis
1. Hepatology; liver transplantation; viral hepatitis and liver fibrosis
2. Regenerative medicine in gastroenterology and hepatology
3. Diagnostic and therapeutics upper and lower gastrointestinal endoscopies
4. Abdominal ultrasound and liver biopsy
5. Hepatic elastometry (fibroscan) liver
Michel Samson has got his PhD in 1993 at University of Paris XI (France). He studied as postdoctoral scientist at Université Libre de Bruxelles (Brussels, Belgium) supported by prestigious fellowships (EMBO, European Community, etc..). He passed two years as visiting scientist at Genentech (California, USA). He is now team leader and director of research at University of Rennes 1 (France) and Irset in Inserm institute, studying the role of cytokines and immune cells in liver pathologies. He has published more than 85 papers in reputed journals (Nature, Cell, J Exp Med, Hepatology, etc..), with already more than 8000 citations and H-index 35.
2. Tumor microenvironment
3. Regulation of angiogenic growth factors
Prof. Sergio Sartori was born on June 22, 1954, and graduated cum laude in 1979. He is specialist in Gastroenterology and in Clinical Pharmacology, is dealing with interventional ultrasonography from 1990, and from 2002 is Chief of the Section of Interventional Ultrasound, St. Anna Hospital, Ferrara, Italy. He is author of more than 246 scientific papers.
Interventional ultrasound; endoscopy
Professor Serrablo is the Chairman of the Hepatopancreatic Biliary Division and Associate Professor of Surgery in Miguel Servet University Hospital, the Zaragoza University, Spain. Dr. Serrablo was twice Visiting Professor in Sàssari University. Currently, Professor Serrablo is the President of Spanish Chapter of International Hepatopancreatic Biliary Association and European-African Hepatopancreatic Biliary Association. Dr. Serrablo has clinical interests in complex liver and pancreas surgery in oncological setting. His medical interests are in health care disparity, medical economics, health policy, and systems development. Dr. Serrablo’s expertise is in liver, pancreas, and bile duct cancer, and their immunohistochemistries as prognostic factors. Professor Serrablo has involved in ALPPS field and small remnant liver volume management.
Professor Serrablo received his medical degree from the University of Zaragoza, and he received his PhD degree in the same University. Dr. Serrablo completed his general surgery residency at Miguel Servet University Hospital. Prof. Serrablo has been involved in several National Health Spanish System grants for researching in liver and pancreas fields.
Subsequently, Dr. Serrablo is a member of the Board in HPB Section and Surgical Infection in Spanish Association of Surgeons. He belongs to the Board of Development Committee of IHPBA Council. He conducted 11 doctoral thesis and publish more than 50 chapter of books and two books and more than 200 oral and poster presentations in national and international congress as well as more than 50 round table chairmen sessions.
Professor Serrablo is a principal researcher in www.livergroup.org to get a standardization in complex liver surgery definition.
Blood; coagulation;laparoscopy; surgery; medicine; hepatobiliary surgery; blood transfusion; surgical techniques; liver; pancreatic surgery; laparoscopic surgery; abdominal surgery; surgical oncology; laparoscopic cholecystectomy; cholecystectomy; general surgery
Member of Development Committee of IHPBA;
President of Spanish Chapter of IHPBA;
Chairman of HBP Surgical Division, Miguel Servet University Hospital, Zaragoza, Spain.
Hematology and hemato-oncopathology; immunocytochemistry &molecular pathology; herbal therapeutics in cancer
Dr. Shilpa Sharma is a faculty (Asst. Professor) of Pediatric Surgery at All India Institute of Medical Sciences, New Delhi. Her qualifications include MBBS - 1996, MS Gen Surgery -1999, MCh and DNB - Pediatric Surgery - 2004. She is involved in the surgical care of children since last 15 years with research interests in stem cells. She has also done PhD on stem cells from All India Institute of Medical Sciences, New Delhi in 2010. Her notable awards include Dr. Shoor Vir Singh Prize, UC Chakravorty Research Award, Shanti Talwar Fellowship, Swapan Datta Research Award, Purushotom Upadhyay Research Award for the best paper published in 2010, James Lister fellowship of the British Association of Pediatric Surgeons in 2012 and the WOFAPS scholarship from the World Federation of Association of Pediatric Surgeons 2014 under which she was a fellow at GOS Hospital for Children at London, UK. She has published 56 research papers and 80 book chapters, delivered more than 60 guest lectures and presented more than 110 papers at various national and international conferences. She has served as an Editorial Assistant for Journal of Indian Association of Pediatric Surgeons and is presently an Editorial Consultant for two International journals apart from being a reviewer of many peer reviewed journals. She has served as Secretary of the Delhi chapter of Indian Association of Pediatric Surgeons from 2011-2014 and is currently the Secretary of the Research Section of the Indian Association of Pediatric Surgeons since 2011.
Virology and oncology
Nicola Silvestris graduated cum laude in 1993 from the Catholic University of Rome School of Medicine, Rome, Italy. He received his Ph.D. degree in 1998. Since graduation, he has become involved in studies on translational research in solid tumors. In this area, he is recognized as a national and international expert, as indicated by the numerous participations in meetings and seminars as an invited speaker. From 2011 he has been involved in the elaboration of guidelines of exocrine pancreatic carcinoma for the Italian Association of Medical Oncology. Since 2015, he is a Founding Member of the Italian Group for Diagnosis and Treatment of Biliary Cancer (GICO). He has published more than 140 papers in peer-reviewed journals. He regularly serves as a reviewer for the most important gastroenterology journals and for funding agencies.
Translational research (predictive and prognostic markers in gastrointestinal malignancies); treatment of gastrointestinal malignancies; conduction of clinical trials
Dr. Singal joined the UAB as an Assistant Professor in the Division of Gastroenterology and Hepatology of the Department of Medicine after completing Masters in Clinical Research from UTMB Galveston TX, and AASLD sponsored advanced fellowship in Transplant Hepatology at the Mayo Clinic, Rochester, MN. Dr. Singal is active in the Faculty practice with clinical and translational research interests of steatohepatitis (due to alcohol use as well as due to non-alcohol fatty liver disease), simultaneous liver-kidney transplantation, and porphyria cutanea tarda.
Steatohepatitis (both alcohol and non-alcohol etiology) related liver disease; interaction of HCV and alcoholic hepatitis; simultaneous liver kidney transplantation allocation; and porphyria cutanea tarda
Cigdem Soydal is working as a Researcher from Ankara University. She is extending her valuable service as a Researcher and has been a recipient of many award and grants. Her research experience includes various programs, contributions and participation in different countries for diverse fields of study. Her research interests as a Researcher reflect in her wide range of publications in various national and international journals.
Oncology; PET/CT; radionuclide treatments
Internal medicine and gastroenterology
Dr. Perumal Subramanian is a Professor of Biochemistry and Biotechnology at Annamalai University, Chidambaram, Tamil Nadu, India. He has made extensive contributions in the fields of hepatocarcinogenesis, liver toxicology, nephrotoxicity and molecular chronobiology. He has published 110 research papers in high impact factor journals. He has been a Visiting Professor at University des Paris, Paris, France and University of Malaya, Malaysia during 2004, 2013 and 2014.
Chronopharmacology; chronotherapeutics and molecular chronobiology
Hepatobiliary and pancreatic surgery; portal hypertension; liver transplantation; hepatic stem cell and the mechanism of liver fibrosis;
1. Portal hypertension
2. Hepatobiliary and pancreatic surgery
3. Hepatic stem cells
4. Immunity of liver transplantation
Internal medicine; medical oncology; hematology; epidemiology
Dr. Tarrass graduated from the University of Casablanca with a Medical Degree and a Diploma of Specialization in Nephrology. After completion of his degrees, he was appointed as a Faculty Fellow at the University Josephy fourier of Grenoble. Dr.Tarrass served as the Head of the Department of Hemodialysis at the Hospital Hassani of Nador and the Department of Hemodialysis at the Hospital of Larache, Morocco. He works actually as a senior consultant Nephrologist at the Hemodialysis Center of 2 Mars in Casablanca, Morocco.
His interests are focused on green nephrology, water conservation practices in hemodialysis and recycling of hemodialysis wastes. Dr. Tarrass is internationally recognized in the Marquis Who's Who of the World. He currently serves on the Editorial Board of numerous medical Journals, and his publications include 50 journal articles and 10 book chapters.
Dr. Tombesi was born on April 27, 1976, and graduated cum laude in 2001. She is specialist in Internal Medicine and is dealing with interventional ultrasonography from 2003. She is working in the Section of Interventional Ultrasound, St. Anna Hospital, Ferrara, Italy, from 2006, and is author of 62 scientific papers.
Dr. Georgios Tsoulfas received his medical degree from Brown University School of Medicine and completed his general surgery residency at the University of Iowa Hospitals and Clinics, as well as a transplant research fellowship at the Starzl Transplant Institute at the University of Pittsburgh. He then completed a two-year transplantation surgery fellowship at the Massachusetts General Hospital, Harvard Medical School and then joined the Division of Solid Organ Transplantation and Hepatobiliary Surgery at the University of Rochester Medical Center as an assistant professor of surgery. He has recently returned to Greece where he is an Assistant Professor of Surgery at the Aristoteleion University of Thessaloniki.The recipient of awards such as the Edward E. Mason award for excellence in patient care and education and a member of the American Society of Transplant Surgeons Bylaws Committee, he is a member of a number of professional organizations including the American Society of Transplant Surgeons, Association for Academic Surgery, International College of Surgeons, American College of Surgeons, International Liver Transplantation Society, American Medical Association, Society for Laparoscopic Surgeons and International HepaticoPancreaticoBilliary Association.
Solid organ transplantation and hepatobiliary surgery
1. Trans-differentiation of stem cell into cardiac tissue; developing patched using biodegradable material and stem cells; hepatictransdifferentiation of human bone marrow mesenchymal stem cells; development and characterization of tissue engineered Xenografts
2. Construction of novel immunotoxins; targeted anticancer therapy with recombinant fungal immunotoxins
3. Fanconi anemia
4. Cloning & expression of therapeutic protein that have clinical importance
5. Development of monoclonal antibodies for targeted therapy
6. Folate receptor a model for targeted approach for cancer
7. Elucidation of various pathways in cancer model using plant oil’s
Mathieu Vinken graduated as a Pharmacist and subsequently obtained the degree of Doctor in Pharmaceutical Sciences at the Vrije Universiteit Brussel (VUB) - Belgium. He is a European registered toxicologist and a trained chemical risk assessor. Dr. Vinken is author of more than fifty scientific publications in peer-reviewed journals and books and is involved in several European research projects in the field of liver-based in vitro modelling. He is currently a Professor at the Department of Toxicology of the VUB-Belgium and his research is situated in the field of experimental and molecular in vitro toxicology.
Imam WAKED is Professor of Medicine in the National Liver Institute (NLI) in Egypt. He graduated Cairo University School of Medicine, and obtained a Master then a Doctorate degree in Medicine from Ain Shams University in Egypt.
He chaired the hepatology department in the NLI in 2002, was vice dean till 2007 and became the dean of the NLI from 2008 till 2011. Professor Waked has more than 60 publications in international and local peer-reviewed journals. His research interests include viral hepatitis and related liver cancer, and portal hypertension and its complications.
Viral hepatitis; hepatitis C; portal hypertension; HCC; ERCP health economics; social impact of disease
Computational biology; systems biology; molecular and cellular biology; biochemistry; cancer; neurobiology; single molecular computational network construction and analysis between normal and disease tissues; integrative functions are proposed involving in not restricting to cancer development; nerve transmission; invasion; cell adhesion; differentiation; apoptosis; cell death; cell maturation; survival; cell growth; migration; aging; cell motility; angiogenesis; vasculogenesis; proliferation; DNA replication; mitosis; integrative mechanisms are setup not limited to the immune response; the process of signal transduction; the cytoskeleton and molecular motors; the properties of membrane channels and transporters; and metabolism
Professor Viroj Wiwanitkit is a medical professor and Asian Scholar. He is presently a visiting University Professor, Hainan Medical University, China. He has more than 950 international journal publications and 150 international textbook publications. He is editor in chief and editorial board of more than 40 journals. He has ever been invited to be keynote speakers of many international conferences. He is the Thai scientists with the most number of publications. He is a guest lecturer of many universities.
1. Tropical medicine
2. Laboratory science (biomedical)
3. Nanoscience and nanotechnology
4. Bioinformatics and medical engineering
5. Family medicine; social medicine and public health
Jack Ho Wong completed his PhD studies at the Chinese University of Hong Kong and currently is a research associate at the School of Biomedical Sciences. He is working on bioactive peptides emphasized on antimicrobial and anticancer effect. He has published more 100 papers in reputed journals and has been serving as an editorial board member in the journals Toxins, Frontiers in Microbiology and Frontiers in Pharmacology and a manuscript reviewer for several journals.
Dr. Yamaguchi graduated from Shizuoka College of Pharmacy (B.S.) in 1971 and obtained Ph.D of Pharmaceutical Sciences in 1976. He was engaged as Research Associate and Assistant Professor in Shizuoka College of Pharmacy (1973-1987). As Assistant Professor in School of Pharmaceutical Sciences, University of Shizuoka(1987-1991). As Associated Professor in University of Shizuoka, Graduate School of Nutritional Sciences (1991-1993) and Professor in University of Shizuoka, Graduate School of Nutritional Sciences (1993 ~ 2007) in Japan. From 2007, Yamaguchi was invited as Visiting Professor, Emory University School of Medicine, Department of Medicine. He was appointed Editorial Board Member of many Journals including International Journal of Molecular Medicine, Molecular Medicine Reports, Journal of Osteoporosis, International Journal of Medicine and Medical Sciences, International Journal of Nutrition and Metabolism, Molecular and Cellular Biochemistry, Endocrinology Studies, Alternative Medicine Studies, Experimental and Therapeutic Medicine, and Stem Cell Discovery. Yamaguchi published over 500 English original papers, review articles and books.
Hematology and biomedical oncology
My research commits to explore the changes of noncoding RNA expression profiles and regulatory networks in the progress of hepatocellular carcinoma (HCC). As the first author, I had published 12 papers in leading journals of medicine, such as Mol Cell and Hepatology. There are two representative papers were recommended and evaluated by Faculty of 1000 experts. Also, my research won several academic prizes, including “ShangHai Outstanding Ph.D. Thesis” and Second Prize of Shanghai Natural Science Award. Moreover, I had been selected as a member in several talent schemes, such as Shanghai Risingstar in Science and Technology.
Hepatocellular carcinoma; Noncoding RNA; Epigenetics
Yang is a professor of Institute of Medicine, Chung Shan Medical University, Taiwan. He has received the Ph.D. degree in molecular biology. In particular, his researches have been focused on pharmacology, cancer metastasis, cancer biology, genetic polymorphism and environment risk factors in cancer.
Pharmacology; cancer metastasis; cancer biology; genetic polymorphism and environment risk factors in cancer
Cell & molecular biology
Hiroshi Yoshida, M.D. is graduated from Nippon Medical School (Bsc) obtained MD and subsequently entered the Department of Surgery in 1986. From 1988 to 1992, He attended Postgraduate course in Department of Surgery, Nippon Medical School and obtained PhD. In 1992, He was appointed clinical fellow of the Department of Surgery, Nippon Medical School. In 2003, He was appointed assistant professor and, in 2005, associated professor of the Department of Surgery, Nippon Medical School. In 2010, He was appointed associated professor of the Department of Surgery, Nippon Medical School Tama Nagayama Hospital. In 2011, he was appointed Chief and Clinical Professor of the Department of Surgery, Nippon Medical School Tama Nagayama Hospital. In 2014, he was appointed Assistant Director of the Nippon Medical School Tama Nagayama Hospital.
Hepato-biliary-pancreatic surgery; portal hypertension; transplantation; interventional radiology; endoscopic treatment
Dr. Yanmin Zhang is a full professor of School of Pharmacy, Health Science Center, Xi'an Jiaotong University of China, member of Chinese Pharmaceutical Association. Yanmin Zhang received his B.S. in chemistry and Ph.D. in pharmaceutical analysis. He began his independent career in 1999. He is currently the director of molecular pharmacology program and assistant research scientist in the Biodesign Institute of Arizona State University, USA. He has held more than 10 national projects, published more than 100 papers including Pharmacol Therapeut, JACS, Org Lett, Chem Commu, CDDs, Sci Rep, Can lett, JCMM , et al. and held 26 patents.
Tumor Cell Biology
Screening of targeted drug
Molecular biology; neurological diseases; drug discovery; cell & tissue engineering; tissue fibrosis targeted therapy; animal genetic engineering; cancers; natural drugs; nano-biotechnology; liver diseases; neurotoxicology